Phase 1 N=297 Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-012/KEYNOTE-012)
Cancer · Solid Tumor
Primary: Number of Participants Experiencing Adverse Events (AEs) — 32; 58; 33; 39 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=9 Pharmacokinetics, Safety and Tolerability of Single-dose Belatacept in Adolescent Kidney Transplant Recipients
Kidney Transplant
Primary: Maximum Observed Serum Concentration (Cmax) of Belatacept — 151 micrograms per milliliter
Phase 3 N=199 Evaluation of Alirocumab in Addition to Lipid-Modifying Therapy in Patients With High Cardiovascular Risk and Hypercholesterolemia in South Korea and Taiwan
Hypercholesterolemia
Primary: Percent Change From Baseline in Calculated LDL-C at Week 24 - Intent-to-Treat (ITT) Analysis — 6.3; -57.1 percent change — p=<0.0001
N/A N=68 Community-Clinic Partnership to Promote Physical Activity in South Asian Women
Diabetes Mellitus · Physical Activity
Primary: Change in Physical Activity (Minutes/Week) — 42; 58 minute/week activity
N/A N=82 Clinical Evaluation of ACUVUE® OASYS® 1-Day and ACUVUE® OASYS®
Refractive Error
Primary: Tear Film Evaporation Rate in a Normal Environment After 10 ± 3 Days of Wear (Pre RH) — 11.97; 10.66; 8.51; 7.94 10^-7g/cm^2/s
N/A N=301 Comparing the Effectiveness of a Mitral Valve Repair Procedure in Combination With Coronary Artery Bypass Grafting (CABG) Versus CABG Alone in People With Moderate Ischemic Mitral Regurgitation
Mitral Valve Insufficiency · Coronary Artery Disease
Primary: Degree of Left Ventricular Remodeling, as Assessed by Left Ventricular End Systolic Volume Index (LVESVI) — 49.6; 46.1 ml per square meter — p=0.61
N/A N=360 The CHICA Developmental Screening Study
Developmental Delay
Primary: Number of Children Screened for Developmental Delay — 153; 44 Participants
Phase 3 N=202 To Evaluate The Safety of SAR153191 (REGN88) and Tocilizumab Added to Other RA Drugs in Patients With RA Who Are Not Responding to or Intolerant of Anti-TNF Therapy (SARIL-RA-ASCERTAIN)
Rheumatoid Arthritis
Primary: Number of Participants With Treatment Emergent Adverse Events (TEAEs) — 33; 36; 68; 1 participants
Phase 3 N=562 Colesevelam as Add-on to Pioglitazone Therapy for Type 2 Diabetes Mellitus
Type 2 Diabetes Mellitus
Primary: Change From Baseline in Hemoglobin A1c (HbA1c) at Week 24 — -0.34; -0.02 percent — p=<0.001
N/A N=240 Evaluation of a Mental Health Physician Support Program in Nova Scotia
Major Depressive Disorder
Primary: Depression Severity (Change in Patient Health Questionnaire-9 (PHQ-9) Score From Baseline — 16.43; 17.28; 11.25; 10.39 units on a scale — p=.047
N/A N=31 Littlears Auditory Questionnaire: Validation Study in CI Children
Hearing Loss
Primary: To Validate the LittleEARS Auditory Questionnaire — 34.75 units on a scale
N/A N=748 D-Dimer Determined Anticoagulation INTENSITY in Patients With Mechanical Valve Replacement
Heart Valve Disease
Primary: Bleeding Events; — 16; 3; 4 Participants
Phase 3 N=132 Evaluation of the Safety of Adjunct Brexpiprazole in Elderly Patients With Major Depressive Disorder and an Inadequate Response to Antidepressant Treatment
Major Depression Disorder
Primary: Number of Patients With Treatment-Emergent Adverse Events — 102 Participants
Phase 3 N=341 A Phase III Long-term Study of TAK-536TCH in Participants With Essential Hypertension
Essential Hypertension
Primary: Number of Participants Who Experience at Least One Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) — 289; 20 Participants
Phase 4 N=17 Descriptive Study of Cardiac Output During Rehydration With Recombinant Human Hyaluronidase in Pediatrics
Dehydration · Cardiac Output · Pediatrics
Primary: Cardiac Output Trends